Study of Oral Fampridine-SR in Multiple Sclerosis

Corinne Goldsmith Dickinson Center for MS, New York

Maimonides Medical Center, Brooklyn

SUNY - Stony Brook, Stony Brook

University of Rochester, Rochester

Allegheny General Hospital, Allegheny Neurological Associates, Pittsburgh

Thomas Jefferson University Physicians, Philadelphia

Maryland Center for MS, Baltimore

Carolinas Healthcare System, Charlotte

Shepard Center, Atlanta

University of Alabama, Birmingham

Ohio State University MS Center, Columbus

Cleveland Clinical Foundation, Cleveland

Indiana University MS Center, Indianapolis

Wayne State University, Department of Neurology, Detroit

The Schapiro Center for MS, Golden Valley

University of Chicago, Chicago

Washington University SOM, St Louis

University of Texas - Houston, Houston

University of Colorado Health Sciences Center, Denver

Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center, Phoenix

University of Mexico, MIND Imaging Center, Albuquerque

USC, Keck School of Medicine, Los Angeles

UC Davis, Sacramento

Oregon Health & Science University, MS Center of Oregon, UHS-42, Portland

MS Hub Medical Group, Seattle

University of Washington, MS Research Center, Seattle

Multiple Sclerosis Treatment Center, Derby

Gimbel MS Center at Holy Name Hospital, Teaneck

Neurological Research Center, Inc., Bennington

Fletcher Allen Health Care, Burlington

Foothills Medical Center, Calgary

University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver

QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site, Halifax

Ottawa Hospital General Campus, Ottawa